相关实验视频

Updated: May 27, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

布罗利祖马布相关的免疫血小板缺血症

Perihan Perkin¹, Serhat Sekmek¹, Dogan Bayram¹

¹Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.

Journal of chemotherapy (Florence, Italy)

|February 20, 2025

概括

免疫检查点抑制剂 (ICI) 可以引起罕见但严重的副作用,如免疫血栓塞缩症. 早期识别和管理对于非小细胞肺癌 (NSCLC) 治疗中的患者安全至关重要.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

免疫检查点抑制剂 (ICI) 已经改变了癌症治疗.
免疫相关不良事件 (irAEs) 是已知的ICI并发症.
抗PD-1抗体的 pembrolizumab 是非小细胞肺癌 (NSCLC) 的常见ICI.

研究的目的:

在转移性NSCLC患者中报告与pembrolizumab相关的免疫血小板缩病例.
要突出管理ICI诱导的血小板缺血的挑战.
强调早期诊断和干预的重要性.

主要方法:

一个55岁的男性患有转移性NSCLC的病例报告.
治疗包括pembrolizumab,卡博普拉丁和pemetrexed.
用皮质类固醇治疗复发性血小板缺血症的治疗,并停止服用潘布罗利祖马布.

主要成果:

患者最初实现了完全的代谢反应.
在 pembrolizumab 治疗期间出现的复发性 3 级血小板缺血症.
血小板缺血症在使用皮质类固醇时得到缓解,但在重新使用后复发.
需要永久停止使用 pembrolizumab.

结论:

布罗利祖马布诱导的免疫血小板缺血是一种罕见但显著的并发症.
及时识别和管理对于患者安全至关重要.
在NSCLC治疗中,平衡瘤结果与irAE管理至关重要.

关键词:

这就是Pembrolizumab.不良事件不良事件不良事件免疫检查点抑制剂免疫检查点抑制剂免疫性血小板减少症.非小细胞肺癌的肺癌.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.